171 related articles for article (PubMed ID: 15685486)
1. [Inhalation therapy with Respimat soft inhaler in patients with COPD and asthma].
Voshaar T; Hausen T; Kardos P; Köhler D; Schultze-Werninghaus G; Schürmann W; Vogelmeier C
Pneumologie; 2005 Jan; 59(1):25-32. PubMed ID: 15685486
[TBL] [Abstract][Full Text] [Related]
2. A review of the development of Respimat Soft Mist Inhaler.
Dalby R; Spallek M; Voshaar T
Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
[TBL] [Abstract][Full Text] [Related]
3. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
[TBL] [Abstract][Full Text] [Related]
4. Novolizer: how does it fit into inhalation therapy?
Magnussen H
Curr Med Res Opin; 2005; 21 Suppl 4():S39-46; discussion S47. PubMed ID: 16138944
[TBL] [Abstract][Full Text] [Related]
5. New liquid aerosol generation devices: systems that force pressurized liquids through nozzles.
Geller DE
Respir Care; 2002 Dec; 47(12):1392-404; discussion 1404-5. PubMed ID: 12467498
[TBL] [Abstract][Full Text] [Related]
6. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
[TBL] [Abstract][Full Text] [Related]
7. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
[TBL] [Abstract][Full Text] [Related]
8. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
Henriet AC; Marchand-Adam S; Mankikian J; Diot P
Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
[TBL] [Abstract][Full Text] [Related]
9. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
Kässner F; Hodder R; Bateman ED
Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
[TBL] [Abstract][Full Text] [Related]
10. Importance of inhaler devices in the management of airway disease.
Virchow JC; Crompton GK; Dal Negro R; Pedersen S; Magnan A; Seidenberg J; Barnes PJ
Respir Med; 2008 Jan; 102(1):10-9. PubMed ID: 17923402
[TBL] [Abstract][Full Text] [Related]
11. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
12. Inhaled ethanolic and aqueous solutions via Respimat Soft Mist Inhaler are well-tolerated in asthma patients.
Patel KR; Pavia D; Lowe L; Spiteri M
Respiration; 2006; 73(4):434-40. PubMed ID: 16484767
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
14. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
[TBL] [Abstract][Full Text] [Related]
15. Inhalatory therapy training: a priority challenge for the physician.
Melani AS
Acta Biomed; 2007 Dec; 78(3):233-45. PubMed ID: 18330086
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
Hodder R; Price D
Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of inhalation therapy in chronic obstructive pulmonary disease and asthma.
Pavia D
Respirology; 1997; 2 Suppl 1():S5-10. PubMed ID: 9400688
[TBL] [Abstract][Full Text] [Related]
18. [Powder inhalation systems].
Kohlhäufl M; Haidl P; Voshaar T; Häussinger K; Köhler D
Dtsch Med Wochenschr; 2004 Sep; 129(39):2048-52. PubMed ID: 15386209
[TBL] [Abstract][Full Text] [Related]
19. Key issues in inhalation therapy in children.
Brand PL
Curr Med Res Opin; 2005; 21 Suppl 4():S27-32. PubMed ID: 16138942
[TBL] [Abstract][Full Text] [Related]
20. Use of Respimat Soft Mist inhaler in COPD patients.
Anderson P
Int J Chron Obstruct Pulmon Dis; 2006; 1(3):251-9. PubMed ID: 18046862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
